51. Scleroderma
466 clinical trials,   536 drugs   (DrugBank: 142 drugs),   110 drug target genes,   210 drug target pathways

Searched query = "Scleroderma", "Systemic sclerosis", "SSc", "dcSSc", "lcSSc"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-jRCTs031200019
01/04/202021/04/2020Gastric emptying in systemic sclerosisEvaluation of gastric emptying in patients with systemic sclerosis and clinical features of patients with delayed gastric emptying Systemic sclerosis
systemic sclerosis, delayed gastric emptying;D012595
Gastric emptying in patients with systemic sclerosis will be evaluated by 13C breath test. In particular, patients will take test meal with acetate labelled with 13C and their breaths will be evaluated.Kuribayashi ShikoUraoka ToshioRecruiting>= 20age oldNot applicableBoth60N/AJapan
2NCT03742466
(ClinicalTrials.gov)
November 10, 201810/11/2018Local Injection of Ozone Versus Methylprednisolone Acetate in Carpal Tunnel Syndrome of Scleroderma PatientsLocal Injection of Ozone Versus Methylprednisolone Acetate in Carpal Tunnel Syndrome of Scleroderma Patients. A Single-blind Randomized Clinical TrialCarpal Tunnel Syndrome;Chronic Pain;SclerodermaDrug: Ozone;Drug: methylprednisolone acetateAssiut UniversityNULLCompleted20 Years60 YearsAll50N/AEgypt
3NCT01257802
(ClinicalTrials.gov)
May 20119/12/2010GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic DiseasesGnRH-a for Ovarian Protection During CYC Therapy for Rheumatic DiseasesLupus Erythematosus, Systemic;Systemic Vasculitis;Isolated Angiitis of Central Nervous System;Lung Disease With Systemic Sclerosis;Lung Disease Interstitial DiffuseDrug: depot leuprolide acetate 3.75 mg;Drug: PlaceboJoseph MccuneNational Institutes of Health (NIH);Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Terminated18 Years40 YearsFemale14Phase 3United States